In this episode, we examine the epidemiology and management of Thromboangiitis Obliterans (Buerger’s disease), a rare inflammatory vasculitis affecting small- and medium-sized vessels that predominantly strikes young tobacco users and can lead to severe limb ischaemia and amputation. We explore the critical role of complete smoking cessation in halting disease progression, the emerging risk factors involving cannabis and vaping, and the potential of novel interventions—such as stem cell therapy, the Ilizarov bone transport technique, and gene therapy—to preserve limbs when traditional revascularisation fails.

In this episode, we explore the paradigm shift in understanding Primary Membranoproliferative Glomerulonephritis (MPGN), moving from a traditional morphological classification to a precise, mechanism-based division between Immune Complex-Mediated MPGN (IC-MPGN) and Complement 3 Glomerulopathy (C3G). We discuss how 2025 marked a turning point for these rare diseases with the FDA approvals of the first targeted complement inhibitors, pegcetacoplan and iptacopan, which offer new hope for stabilizing kidney function and managing the high risk of disease recurrence following transplantation.

In this episode, we explore Hereditary Hemorrhagic Telangiectasia (HHT), a genetic vascular disorder characterized by nosebleeds, mucocutaneous telangiectases, and arteriovenous malformations (AVMs) in major organs. We break down the latest research on the "two-hit" mutation mechanism driving these lesions, review the essential Curaçao diagnostic criteria, and discuss how systematic screening and emerging therapies like pomalidomide and bevacizumab are improving life expectancy and quality of life for patients.

In this episode, we explore Acute Peripheral Arterial Occlusion (APAO), a critical vascular emergency characterised by a sudden decrease in limb perfusion that threatens tissue viability. We break down the classic "6 Ps" of clinical presentation—pain, pallor, pulselessness, paraesthesia, paralysis, and poikilothermia—and review the latest 2024 guidelines on revascularisation strategies, ranging from catheter-directed thrombolysis to mechanical aspiration thrombectomy. Finally, we discuss the management of complications such as reperfusion injury and the necessity of early fasciotomy to prevent limb loss.

In this episode, we explore X-linked ichthyosis (XLI) as more than a skin disorder, focusing on its genetic basis in STSloss on Xp22.3. We explain how disrupted cholesterol sulfate metabolism causes the characteristic scaling, and how larger deletions can affect neighboring genes, leading to short stature, hypogonadism, skeletal changes, and neurodevelopmental traits such as ADHD and autism features. We highlight the often-overlooked impact on female carriers, including ocular findings, postpartum psychiatric risk, and prolonged labor. Finally, we discuss modern MLPA diagnostics and emerging treatments that target the underlying metabolic defect rather than symptoms alone.

In this episode, we explore Trisomy 18, also known as Edwards syndrome, a rare genetic condition caused by the presence of an extra chromosome 18. We discuss the complex medical challenges associated with the diagnosis, including severe developmental delays, heart defects, and distinctive physical features such as clenched fists. Finally, we examine the evolving medical landscape moving from a historical "lethal" label to a life-limiting classification, highlighting how shared decision-making is empowering families to choose between comfort care and active medical interventions.

In this episode, we examine gastroschisis, a congenital defect characterized by the protrusion of the bowel through an abdominal wall opening, typically to the right of the umbilical cord. We distinguish between simple and complex cases, noting that complex gastroschisis—defined by the presence of bowel atresia, volvulus, perforation, or necrosis—is associated with significantly higher rates of morbidity and mortality compared to simple cases. The discussion highlights the use of prenatal ultrasound markers, particularly intra-abdominal bowel dilation and polyhydramnios, to predict these complex outcomes and guide delivery planning. Finally, we review postnatal management strategies, including bowel protection, fluid resuscitation, and surgical closure techniques, emphasizing that while complex cases require longer hospital stays, the overall survival rate in high-resource settings exceeds 90%.

In this episode, we examine Familial Isolated Dilated Cardiomyopathy (ORPHA:154), a genetic disorder where the left ventricle dilates and weakens without external causes like coronary artery disease. We explore the critical role of genetic testing, highlighting how specific mutations—such as those in TTN or LMNA—dictate prognosis and the risk of sudden cardiac death,. Finally, we discuss the importance of cascade screening for family members and review treatment options, ranging from standard heart failure medications to implantable defibrillators and emerging gene therapies,,.

In this episode, we unpack Hypoplastic Left Heart Syndrome (HLHS), examining risk factors ranging from genetic variants to maternal exposure to organic dust and heavy metals. We discuss the life-saving three-stage surgical palliation and how home monitoring programs tracking weight and oxygen saturation have drastically reduced mortality during the critical interstage period. Finally, we address managing long-term Fontan circulation complications, including Fontan-associated liver disease (FALD) and protein-losing enteropathy.

In this episode, we explore Pemphigus Vulgaris, a rare and potentially life-threatening autoimmune disorder where antibodies attack desmoglein proteins, causing painful blistering of the skin and mucous membranes. We discuss the critical shift in therapeutic management from high-dose corticosteroids to the use of the biologic agent Rituximab as a first-line treatment to induce long-term remission. Finally, we examine the importance of early diagnosis via immunofluorescence and biopsy, as well as the role of genetic factors and environmental triggers in disease onset.